Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
SOLUTION
**DOSAGE AND ADMINISTRATION** The recommended dose is one drop of ALPHAGAN® in the affected eye(s) two times daily. For those patients whose IOP peaks in the afternoon or need additional IOP control, an additional drop of brimonidine in the afternoon can be added. If more than one topical ophthalmic drug is to be used, the different drugs should be instilled at least 5 minutes apart.
OPHTHALMIC
Medical Information
**INDICATIONS AND USAGE** ALPHAGAN® is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The IOP lowering efficacy of ALPHAGAN® ophthalmic solution diminishes over time in some patients. This loss of effect appears with a variable time of onset in each patient and should be closely monitored.
**CONTRAINDICATIONS** ALPHAGAN® is contraindicated in patients with hypersensitivity to brimonidine tartrate or any component of this medication. It is also contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy and contraindicated in neonates and infants (children under the age of 2 years).
S01EA05
brimonidine
Manufacturer Information
ABBVIE PTE. LTD.
ALLERGAN PHARMACEUTICALS IRELAND
Active Ingredients
Documents
Package Inserts
Alphagan Ophthalmic Solution 0.2% PI.pdf
Approved: July 9, 2020